Health Care

Insider sales at Acme United show routine liquidity moves, not panic: Olschan’s recent 4,833‑share sale keeps investor confidence steady while the company’s fundamentals remain solid.

Explore Eton Pharma’s insider sales: CEO Sean Brynjelsen’s tactical off‑load and its impact on the stock’s growth outlook and investor strategy.

Insider Sangiovanni’s new 40k options/20k RSUs show Zevra’s confidence as stock surges 15.65% weekly, 19.96% monthly – a bullish shift for long‑term investors.

Kevin Gordon’s modest sale of 5,500 Progyny shares at $24.99 shows routine liquidity, not a shift in confidence, amid strong monthly gains and insider buying.

CEO Eric Lefkofsky’s Rule‑10b5‑1 sale of 166,250 Tempus AI shares—$8.4 M—shows a planned divestment amid a 20% year‑to‑date decline, highlighting insider strategy vs. market sentiment.

Illumina insider trading shows strategic buying after bulk sells, linked to new oncology platforms and strong market sentiment—investors should watch the 2026 activity for momentum clues.

Insider buying by Stuka Paul boosts confidence in InspireMD’s biotech stock despite recent decline, hinting at a potential rebound as its acute myocardial infarction device advances.

KalVista insider Yea Christopher buys 33,800 shares at $7.07, a deep discount to $26.77, signaling confidence in EKTERLY’s future and investor buzz.

ElectroCore CFO Lev Joshua S. sells 3,000 shares for tax purposes—routine move with no impact on the company’s bullish outlook.

Fromkin’s strategic buying of Immunovant shares signals a cautious long‑term optimism amid the company’s strong growth but negative P/E, offering investors a nuanced insider perspective.